keyword
https://read.qxmd.com/read/38699609/neural-dynamic-foundations-of-a-theory-of-higher-cognition-the-case-of-grounding-nested-phrases
#1
JOURNAL ARTICLE
Daniel Sabinasz, Mathis Richter, Gregor Schöner
Because cognitive competences emerge in evolution and development from the sensory-motor domain, we seek a neural process account for higher cognition in which all representations are necessarily grounded in perception and action. The challenge is to understand how hallmarks of higher cognition, productivity, systematicity, and compositionality, may emerge from such a bottom-up approach. To address this challenge, we present key ideas from Dynamic Field Theory which postulates that neural populations are organized by recurrent connectivity to create stable localist representations...
April 2024: Cognitive Neurodynamics
https://read.qxmd.com/read/38693662/are-we-closer-to-a-standard-of-care-for-richter-s-syndrome-novel-treatments-on-the-horizon
#2
REVIEW
Nghia Pham, Catherine C Coombs, Susan O'Brien
INTRODUCTION: The therapeutic landscape for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved over the past decade with dramatically improved outcomes with the introduction of targeted therapies. This unfortunately has not been the case for Richter transformation (RT), the histologic transformation to a more aggressive lymphoma, most typically diffuse large B-cell lymphoma (DLBCL). As such, RT continues to be one of the most challenging complications of CLL/SLL...
May 1, 2024: Expert Review of Hematology
https://read.qxmd.com/read/38691072/pseudo-richter-transformation-of-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-after-temporary-acalabrutinib-interruption
#3
JOURNAL ARTICLE
Min Shi, Ji Yuan
No abstract text is available yet for this article.
April 30, 2024: Mayo Clinic Proceedings
https://read.qxmd.com/read/38685438/design-and-evaluation-of-nanostructured-lipid-carrier-of-bergenin-isolated-from-pentaclethra-macrophylla-for-anti-inflammatory-effect-on-lipopolysaccharide-induced-inflammatory-responses-in-macrophages
#4
JOURNAL ARTICLE
Petra Obioma Nnamani, Chinekwu Nwagwu, Edith Obioma Diovu, Obiora Emmanuel Abonyi, Mariia Nesterkina, Tobias Neu, Clémentine Richter, Brigitta Loretz, Claus-Michael Lehr
Herein, we report the properties of nanostructured lipid carriers (NLCs) prepared with a gradient concentration of Bergenin (BGN) isolated from Pentaclethra macrophylla stem bark powder. A gradient concentration of BGN (BGN 0, 50, 100, 150, and 200 mg) was prepared in a 5 % lipid matrix consisting of Transcutol HP (75 %), Phospholipon 90H (15 %), and Gelucire 43/01 (10 %) to which a surfactant aqueous phase consisting of Tween 80, sorbitol, and sorbic acid was dissolved. The NLCs were evaluated by size, polydispersity index (PDI), zeta potential, Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), encapsulation efficiency, and in vitro drug release...
April 27, 2024: European Journal of Pharmaceutics and Biopharmaceutics
https://read.qxmd.com/read/38646840/pet-ct-in-leukemia-utility-and-future-directions
#5
JOURNAL ARTICLE
Akram Al-Ibraheem, Sudqi Allouzi, Ahmed Saad Abdlkadir, Miriam Mikhail-Lette, Kamal Al-Rabi, Mohammad Ma'koseh, Peter Knoll, Zaid Abdelrhman, Omar Shahin, Malik E Juweid, Diana Paez, Egesta Lopci
2-Deoxy-2-[18F]fluoro-d-glucose PET/computed tomography ([18F]FDG PET/CT) has proven to be a sensitive method for the detection and evaluation of hematologic malignancies, especially lymphoma. The increasing incidence and mortality rates of leukemia have raised significant concerns. Through the utilization of whole-body imaging, [18F]FDG PET/CT provides a thorough assessment of the entire bone marrow, complementing the limited insights provided by biopsy samples. In this regard, [18F]FDG PET/CT has the ability to assess diverse types of leukemia The utilization of [18F]FDG PET/CT has been found to be effective in evaluating leukemia spread beyond the bone marrow, tracking disease relapse, identifying Richter's transformation, and assessing the inflammatory activity associated with acute graft versus host disease...
April 22, 2024: Nuclear Medicine Communications
https://read.qxmd.com/read/38627181/practical-aspects-of-immunotherapy-a-report-from-the-20th-international-myeloma-society-ims-annual-meeting
#6
JOURNAL ARTICLE
Noopur S Raje, Adam D Cohen, Krina K Patel, Niels W C J van de Donk, Joshua Richter, Jesus San-Miguel
Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies...
March 22, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38604800/-biological-characteristics-and-clinical-significance-of-stereotyped-b-cell-receptor-in-chronic-lymphocytic-leukemia
#7
JOURNAL ARTICLE
T L Qiu, J Y Li, Y Xia
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western adults, although the incidence of CLL is relatively low in Asian populations. However, with the aging population, the incidence of CLL is increasing in China. The interaction between CLL cells and the microenvironment plays a crucial role in the recognition of antigens by the B-cell receptor immunoglobulin (BCR IG). The mutational status of the immunoglobulin heavy variable region (IGHV) is a classical prognostic marker for CLL. Over 40% of CLL patients exhibit biased usage of IGHV and highly similar amino acid sequences in the heavy complementarity-determining region 3 (HCDR3), known as the BCR stereotypy...
February 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38581019/mesenchymal-stromal-cell-chondrogenesis-under-alk1-2-3-specific-bmp-inhibition-a-revision-of-the-prohypertrophic-signalling-network-concept
#8
JOURNAL ARTICLE
Solvig Diederichs, Simon I Dreher, Sarah Anna Nüesch, Sven Schmidt, Christian Merle, Wiltrud Richter
BACKGROUND: In vitro chondrogenesis of mesenchymal stromal cells (MSCs) driven by the essential chondro-inducer transforming growth factor (TGF)-β is instable and yields undesired hypertrophic cartilage predisposed to bone formation in vivo. TGF-β can non-canonically activate bone morphogenetic protein-associated ALK1/2/3 receptors. These have been accused of driving hypertrophic MSC misdifferentiation, but data remained conflicting. We here tested the antihypertrophic capacity of two highly specific ALK1/2/3 inhibitors - compound A (CompA) and LDN-212854 (LDN21) - in order to reveal potential prohypertrophic contributions of these BMP/non-canonical TGF-β receptors during MSC in vitro chondrogenesis...
April 5, 2024: Stem Cell Research & Therapy
https://read.qxmd.com/read/38552193/anti-cd19-chimeric-antigen-receptor-t-cell-therapy-for-richter-transformation-an-international-multicenter-retrospective-study
#9
JOURNAL ARTICLE
Adam S Kittai, David Bond, Ying Huang, Seema A Bhat, Emily Blyth, John C Byrd, Julio C Chavez, Matthew S Davids, Jamie P Dela Cruz, Mark R Dowling, Caitlyn Duffy, Carrie Ho, Caron Jacobson, Samantha Jaglowski, Nitin Jain, Kevin H Lin, Cecelia Miller, Christine McCarthy, Zulfa Omer, Erin Parry, Manoj Rai, Kerry A Rogers, Aditi Saha, Levanto Schachter, Hamish Scott, Jayastu Senapati, Mazyar Shadman, Tanya Siddiqi, Deborah M Stephens, Vinay Vanguru, William Wierda, Jennifer A Woyach, Philip A Thompson
PURPOSE: Outcomes for Richter transformation (RT) are poor with current therapies. The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for RT are not established. METHODS: We performed an international multicenter retrospective study of patients with RT who received CAR-T. Patient, disease, and treatment characteristics were summarized using descriptive statistics, and modeling analyses were used to determine association with progression-free survival (PFS) and overall survival (OS)...
March 29, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38540747/changes-in-gravitaxis-and-gene-expression-in-an-euglena-gracilis-culture-over-time
#10
JOURNAL ARTICLE
Julia Krüger, Peter Richter, Julia Stoltze, Binod Prasad, Sebastian M Strauch, Marcus Krüger, Adeel Nasir, Michael Lebert
Age-dependent changes in the transcription levels of 5-day-old Euglena gracilis cells, which showed positive gravitaxis, 6-day-old cells without gravitactic orientation, and older cells (9- and 11-day-old, which displayed a precise negative gravitaxis) were determined through microarray analysis. Hierarchical clustering of four independent cell cultures revealed pronounced similarities in transcription levels at the same culture age, which proves the reproducibility of the cultivation method. Employing the non-oriented cells from the 6-day-old culture as a reference, about 2779 transcripts were found to be differentially expressed...
March 9, 2024: Biomolecules
https://read.qxmd.com/read/38537065/a-multicenter-study-of-venetoclax-based-treatment-for-patients-with-richter-transformation-of-chronic-lymphocytic-leukemia
#11
JOURNAL ARTICLE
Paul Joseph Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger, Matthew S Davids, Wei Ding, Alessandra Ferrajoli, Jonathan Mitry Hyak, Nitin Jain, Saad S Kenderian, Yucai Wang, William G Wierda, Jennifer A Woyach, Sameer A Parikh, Philip A Thompson
Patients with chronic lymphocytic leukemia (CLL) who develop Richter transformation (RT) have a poor prognosis when treated with chemoimmunotherapy regimens used for de novo diffuse large B-cell lymphoma. Venetoclax, a BCL2 inhibitor, has single agent efficacy in patients with RT and is potentially synergistic with chemoimmunotherapy. In this multicenter, retrospective study, we evaluated 62 patients with RT who received venetoclax-based treatment outside of a clinical trial, in combination with a Bruton tyrosine kinase inhibitor (BTKi; n=28), R-CHOP (n=13), or intensive chemoimmunotherapy other than R-CHOP (n=21)...
March 27, 2024: Blood Advances
https://read.qxmd.com/read/38523019/prognostication-in-chronic-lymphocytic-leukemia
#12
JOURNAL ARTICLE
Riccardo Moia, Gianluca Gaidano
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries. CLL is a highly heterogeneous disease: some patients may never require therapy and others relapse several times after different therapeutic strategies. Therefore, in CLL, prognostic markers are essential to capture high-risk patients for different clinical endpoints including early treatment requirement, early progression after BTK or BCL2 inhibitors and Richter transformation. In early stage CLL, different biological and clinical biomarkers have been identified to predict time to treatment requirement that could be used to identify the most appropriate population for early intervention clinical trial...
March 1, 2024: Seminars in Hematology
https://read.qxmd.com/read/38503942/allogeneic-hematopoietic-stem-cell-transplantation-for-patients-with-richter-transformation-a-retrospective-study-on-behalf-of-the-chronic-malignancies-working-party-of-the-ebmt
#13
JOURNAL ARTICLE
Romain Guièze, Diderik-Jan Eikema, Linda Koster, Johannes Schetelig, Henrik Sengeloev, Jakob Passweg, Jürgen Finke, Mutlu Arat, Annoek E C Broers, Friedrich Stölzel, Jenny Byrne, Cristina Castilla-Llorente, Peter Dreger, Matthias Eder, Tobias Gedde-Dahl, Nicolaus Kröger, Josep Maria Ribera Santasusana, Deborah Richardson, Alessandro Rambaldi, Lucrecia Yañez, Michel Van Gelder, Joanna Drozd-Sokolowska, Kavita Raj, Ibrahim Yakoub-Agha, Olivier Tournilhac, Donal P McLornan
Management of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3-63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9-11) and 28 (42.4%) were in complete remission (CR). The majority underwent reduced intensity conditioning (66.2%) using peripheral blood derived stem cells...
March 19, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38434151/a%C3%A2-%C3%A2-avd-for-treatment-of-hodgkin-lymphoma-variant-of-richter-s-transformation
#14
Benjamin Heyman, Michael Choi, Thomas J Kipps
Hodgkin lymphoma variant of Richter's transformation (HvRT) is a rare complication for patients with chronic lymphocytic leukemia (CLL), with an overall poor prognosis. We present the first known case series of patients with HvRT treated with the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A + AVD). In our series of 4 patients, two patients treated with A + AVD for HvRT had durable remissions of 40 and 42 months, while two patients had disease progression and ultimately died...
2024: Case Reports in Hematology
https://read.qxmd.com/read/38402867/oncogenic-mtor-signaling-axis-compensates-btk-inhibition-in-a-chronic-lymphocytic-leukemia-patient-with-richter-transformation-a-case-report-and-review-of-the-literature
#15
Thomas Parigger, Stephan Drothler, Christian Scherhäufl, Franz Josef Gassner, Maria Schubert, Markus Steiner, Jan Philip Höpner, Alexandra Hödlmoser, Lena Schultheis, Aryunni Abu Bakar, Daniel Neureiter, Lisa Pleyer, Alexander Egle, Richard Greil, Roland Geisberger, Nadja Zaborsky
INTRODUCTION: Targeting the B cell receptor (BCR) pathway via ibrutinib, a specific inhibitor of Bruton's tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus becoming a preferred first line option independent of risk factors. However, acquired resistance to ibrutinib poses a major clinical problem and requires the development of novel treatment combinations to increase efficacy and counteract resistance development and clinical relapse rates...
February 24, 2024: Acta Haematologica
https://read.qxmd.com/read/38399491/2-18-f-fdg-pet-ct-semiquantitative-and-radiomics-predictive-parameters-of-richter-s-transformation-in-cll-patients
#16
JOURNAL ARTICLE
Domenico Albano, Anna Calabrò, Francesco Dondi, Francesco Bertagna
Background and Objectives : Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in developed countries, which can evolve into aggressive lymphoma variants, a process called Richter transformation (RT). The aim of this retrospective study was to analyze the role of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (2-[18F]-FDG PET/CT) and its semiquantitative and radiomics features in detecting RT and evaluate the impact on overall survival (OS). Materials and Methods : One hundred and thirty-seven patients with histologically proven CLL were retrospectively recruited...
January 24, 2024: Medicina
https://read.qxmd.com/read/38368146/the-molecular-map-of-cll-and-richter-s-syndrome
#17
JOURNAL ARTICLE
Amit Sud, Erin M Parry, Catherine J Wu
Clonal expansion of B-cells, from the early stages of monoclonal B-cell lymphocytosis through to chronic lymphocytic leukemia (CLL), and then in some cases to Richter's syndrome (RS) provides a comprehensive model of cancer evolution, notable for the marked morphological transformation and distinct clinical phenotypes. High-throughput sequencing of large cohorts of patients and single-cell studies have generated a molecular map of CLL and more recently, of RS, yielding fundamental insights into these diseases and of clonal evolution...
January 23, 2024: Seminars in Hematology
https://read.qxmd.com/read/38356782/plasmon-determined-selectivity-in-photocatalytic-transformations-on-gold-and-gold-palladium-nanostructures
#18
JOURNAL ARTICLE
Zhandong Li, Sadaf Ehtesabi, Siddhi Gojare, Martin Richter, Stephan Kupfer, Stefanie Gräfe, Dmitry Kurouski
Noble metal nanostructures absorb light producing coherent oscillations of the metal's electrons, so-called localized surface plasmon resonances (LSPRs). LSPRs can decay generating hot carriers, highly energetic species that trigger chemical transformations in the molecules located on the metal surfaces. The number of chemical reactions can be expanded by coupling noble and catalytically active metals. However, it remains unclear whether such mono- and bimetallic nanostructures possess any sensitivity toward one or another chemical reaction if both of them can take place in one molecular analyte...
September 20, 2023: ACS Photonics
https://read.qxmd.com/read/38338868/treatment-of-double-refractory-chronic-lymphocytic-leukemia-an-unmet-clinical-need
#19
REVIEW
Przemysław Zygmunciak, Tadeusz Robak, Bartosz Puła
Recent years have seen significant improvement in chronic lymphocytic leukemia (CLL) management. Targeting B-cell lymphoma (BCL-2) and Bruton's kinase (BTK) have become the main strategies to restrain CLL activity. These agents are generally well tolerated, but the discontinuation of these therapies happens due to resistance, adverse effects, and Richter's transformation. A growing population of patients who have previously used both BTK inhibitors and BCL2 suffer from the constriction of the following regimens...
January 27, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38316549/long-term-remission-in-a-patient-with-relapsed-richter-s-transformation-treated-with-cd19-directed-chimeric-antigen-receptor-t-cells-after-allogeneic-stem-cell-transplantation
#20
Nadine Kutsch, Philipp Gödel, Conrad-Amadeus Voltin, Michael Hallek, Christof Scheid, Peter Borchmann, Udo Holtick
Patients with Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL-RT) face a dismal prognosis. A 51-year-old female patient diagnosed with CLL with deletion (17p) in 2009. CLL treatment included chemoimmunotherapy and targeted substances. DLBCL-RT was diagnosed in November 2016. After receiving an allogeneic hematopoietic stem cell transplantation, she relapsed in September 2019 and tisagenlecleucel was infused in December 2019. Cytokine release syndrome grade 2 was treated with two doses of tocilizumab and the patient was started on 140 mg ibrutinib in February 2020...
February 5, 2024: European Journal of Haematology
keyword
keyword
90479
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.